189 related articles for article (PubMed ID: 34052829)
1. Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome.
Mancini V; Maeder J; Bortolin K; Schneider M; Schaer M; Eliez S
Transl Psychiatry; 2021 May; 11(1):336. PubMed ID: 34052829
[TBL] [Abstract][Full Text] [Related]
2. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.
Vorstman JA; Breetvelt EJ; Duijff SN; Eliez S; Schneider M; Jalbrzikowski M; Armando M; Vicari S; Shashi V; Hooper SR; Chow EW; Fung WL; Butcher NJ; Young DA; McDonald-McGinn DM; Vogels A; van Amelsvoort T; Gothelf D; Weinberger R; Weizman A; Klaassen PW; Koops S; Kates WR; Antshel KM; Simon TJ; Ousley OY; Swillen A; Gur RE; Bearden CE; Kahn RS; Bassett AS;
JAMA Psychiatry; 2015 Apr; 72(4):377-85. PubMed ID: 25715178
[TBL] [Abstract][Full Text] [Related]
3. Predicting Cognition and Psychosis in Young Adults With 22q11.2 Deletion Syndrome.
Antshel KM; Fremont W; Ramanathan S; Kates WR
Schizophr Bull; 2017 Jul; 43(4):833-842. PubMed ID: 27798222
[TBL] [Abstract][Full Text] [Related]
4. The interaction between neurocognitive functioning, subthreshold psychotic symptoms and pharmacotherapy in 22q11.2 deletion syndrome: A longitudinal comparative study.
Weinberger R; Weisman O; Guri Y; Harel T; Weizman A; Gothelf D
Eur Psychiatry; 2018 Feb; 48():20-26. PubMed ID: 29331595
[TBL] [Abstract][Full Text] [Related]
5. Neurocognitive profile in psychotic versus nonpsychotic individuals with 22q11.2 deletion syndrome.
Weinberger R; Yi J; Calkins M; Guri Y; McDonald-McGinn DM; Emanuel BS; Zackai EH; Ruparel K; Carmel M; Michaelovsky E; Weizman A; Gur RC; Gur RE; Gothelf D
Eur Neuropsychopharmacol; 2016 Oct; 26(10):1610-8. PubMed ID: 27524298
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal perspectives on the psychosis spectrum in 22q11.2 deletion syndrome.
Tang SX; Gur RE
Am J Med Genet A; 2018 Oct; 176(10):2192-2202. PubMed ID: 29048724
[TBL] [Abstract][Full Text] [Related]
7. Social cognition in 22q11.2 deletion syndrome and idiopathic developmental neuropsychiatric disorders.
Jalal R; Nair A; Lin A; Eckfeld A; Kushan L; Zinberg J; Karlsgodt KH; Cannon TD; Bearden CE
J Neurodev Disord; 2021 Apr; 13(1):15. PubMed ID: 33863277
[TBL] [Abstract][Full Text] [Related]
8. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
[TBL] [Abstract][Full Text] [Related]
9. Altered cortical thickness development in 22q11.2 deletion syndrome and association with psychotic symptoms.
Bagautdinova J; Zöller D; Schaer M; Padula MC; Mancini V; Schneider M; Eliez S
Mol Psychiatry; 2021 Dec; 26(12):7671-7678. PubMed ID: 34253864
[TBL] [Abstract][Full Text] [Related]
10. Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness.
Ching CRK; Gutman BA; Sun D; Villalon Reina J; Ragothaman A; Isaev D; Zavaliangos-Petropulu A; Lin A; Jonas RK; Kushan L; Pacheco-Hansen L; Vajdi A; Forsyth JK; Jalbrzikowski M; Bakker G; van Amelsvoort T; Antshel KM; Fremont W; Kates WR; Campbell LE; McCabe KL; Craig MC; Daly E; Gudbrandsen M; Murphy CM; Murphy DG; Murphy KC; Fiksinski A; Koops S; Vorstman J; Crowley TB; Emanuel BS; Gur RE; McDonald-McGinn DM; Roalf DR; Ruparel K; Schmitt JE; Zackai EH; Durdle CA; Goodrich-Hunsaker NJ; Simon TJ; Bassett AS; Butcher NJ; Chow EWC; Vila-Rodriguez F; Cunningham A; Doherty J; Linden DE; Moss H; Owen MJ; van den Bree M; Crossley NA; Repetto GM; Thompson PM; Bearden CE
Am J Psychiatry; 2020 Jul; 177(7):589-600. PubMed ID: 32046535
[TBL] [Abstract][Full Text] [Related]
11. Trajectories of psychiatric diagnoses and medication usage in youth with 22q11.2 deletion syndrome: a 9-year longitudinal study.
Kates WR; Mariano MA; Antshel KM; Chandra S; Gamble H; Giordano M; MacMaster E; Mattar M; St Fleur D; Faraone SV; Fremont WP
Psychol Med; 2019 Aug; 49(11):1914-1922. PubMed ID: 30226117
[TBL] [Abstract][Full Text] [Related]
12. The Psychosis Spectrum in 22q11.2 Deletion Syndrome Is Comparable to That of Nondeleted Youths.
Tang SX; Moore TM; Calkins ME; Yi JJ; Savitt A; Kohler CG; Souders MC; Zackai EH; McDonald-McGinn DM; Emanuel BS; Gur RC; Gur RE
Biol Psychiatry; 2017 Jul; 82(1):17-25. PubMed ID: 27832840
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Autoimmune Psychosis in Chromosome 22q11.2 Deletion Syndrome.
Ciano-Petersen NL; Hamad-Cueto O; Drissi-Reyes H; Doña-Díaz Á; García-Martín G
Front Immunol; 2021; 12():708625. PubMed ID: 34721378
[TBL] [Abstract][Full Text] [Related]
14. Positive psychotic symptoms are associated with divergent developmental trajectories of hippocampal volume during late adolescence in patients with 22q11DS.
Mancini V; Sandini C; Padula MC; Zöller D; Schneider M; Schaer M; Eliez S
Mol Psychiatry; 2020 Nov; 25(11):2844-2859. PubMed ID: 31164700
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities in brain white matter in adolescents with 22q11.2 deletion syndrome and psychotic symptoms.
Kikinis Z; Cho KIK; Coman IL; Radoeva PD; Bouix S; Tang Y; Eckbo R; Makris N; Kwon JS; Kubicki M; Antshel KM; Fremont W; Shenton ME; Kates WR
Brain Imaging Behav; 2017 Oct; 11(5):1353-1364. PubMed ID: 27730479
[TBL] [Abstract][Full Text] [Related]
16. Early language measures associated with later psychosis features in 22q11.2 deletion syndrome.
Solot CB; Moore TM; Crowley TB; Gerdes M; Moss E; McGinn DE; Emanuel BS; Zackai EH; Gallagher S; Calkins ME; Ruparel K; Gur RC; McDonald-McGinn DM; Gur RE
Am J Med Genet B Neuropsychiatr Genet; 2020 Sep; 183(6):392-400. PubMed ID: 32715620
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome.
Kontoangelos K; Lazaratou E; Economou M; Yiannopoulou KG; Papageorgiou CC
Psychopharmacol Bull; 2020 Mar; 50(1):35-39. PubMed ID: 32214520
[TBL] [Abstract][Full Text] [Related]
18. Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated.
Tang SX; Yi JJ; Calkins ME; Whinna DA; Kohler CG; Souders MC; McDonald-McGinn DM; Zackai EH; Emanuel BS; Gur RC; Gur RE
Psychol Med; 2014 Apr; 44(6):1267-77. PubMed ID: 24016317
[TBL] [Abstract][Full Text] [Related]
19. White matter abnormalities in 22q11.2 deletion syndrome patients showing cognitive decline.
Nuninga JO; Bohlken MM; Koops S; Fiksinski AM; Mandl RCW; Breetvelt EJ; Duijff SN; Kahn RS; Sommer IEC; Vorstman JAS
Psychol Med; 2018 Jul; 48(10):1655-1663. PubMed ID: 29143717
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal trajectories of cortical thickness as a biomarker for psychosis in individuals with 22q11.2 deletion syndrome.
Ramanathan S; Mattiaccio LM; Coman IL; Botti JC; Fremont W; Faraone SV; Antshel KM; Kates WR
Schizophr Res; 2017 Oct; 188():35-41. PubMed ID: 27988073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
